Sector: Healthcare
Country: Poland
Responsible Advisor:
Fund: EQT V
Entry: Dec 2009
Exit: Jul 2018

HTL-Strefa is the globally unrivalled, leading developer and provider of blood micro-sampling medical devices with a 44% global market share by volume in safety lancets and a strong and growing global position in personal lancets and pen needles.

The blood sampling lancets are used for single-use capillary blood testing, while pen needles are used for hypodermic injections, mainly addressing the growing global diabetes patient population, point-of-care testing, and increasing safety compliance of professional care.

HTL-Strefa sells its products in over 80 countries and provide products to two target groups of end users: professional care customers such as hospitals and nursing homes, as well as home care customers, which include diabetes patients. The Company manufactures and sells more than two billion high quality lancets and pen needles per year.

About a quarter of HTL-Strefa's sales are sold under HTL-Strefa's own brands through distributors and hospitals, with the remaining sales being based on long-term contracts with leading diabetes companies and distributors. HTL-Strefa is known for high quality and the products are protected by patents and governed by tight regulatory requirements (such as FDA requirements for medical devices). HTL-Strefa has two modern and automated production facilities in central Poland, which benefit from integrated in-sourced needle grinding and plastic molding as well as a focused packaging and storage facility in the US. HTL-Strefa has industry-leading technological and production process knowledge which ensures best-in-class quality, efficiency, innovation and profitability.

The origins of HTL-Strefa go back to 1995 when production of lancets was started. The company was listed on the Warsaw stock exchange in 2006 and was acquired by EQT in 2009 in a take-private transaction.

Visit HTL-Strefa

Key events since EQT investment

  • Management strengthened across the board during EQT ownership including recent recruitment of new CEO Mikkel Danvold. For press release, please read here.
  • New quality management system implemented and audited by several regulators and diabetes corporate customers in the second quarter of 2010
  • Expansion into a new product category with launch of pen needle sales in the fourth quarter of 2010. Pen needles are disposable hollow needles used by diabetes patients in insulin pens
  • Plant expansion and investment program is ongoing with the aim of supporting expected sales growth in safety lancets and the ramp-up of pen needle sales
  • Introduced new lancing device in 2013 for integrated use with personal lancets in the home care market, offering the patient an adjustable skin penetration for individual user comfort
  • Launched state-of-the-art next generation pen needle during 2014